Amgen reports a Phase 3 win with Sjögren’s drug candidate
Published . Updated .
Dazodalibep, acquired in Amgen’s big buyout of Horizon Therapeutics, succeeded in the first of two late-stage trials against the tough-to-treat autoimmune disorder.
Directly affected
- AMGN Amgen
Named in this report.
Indirectly affected
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GEHC GE HEALTHCARE TECHNOLOGIES I
GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Dazodalibep, acquired in Amgen’s big buyout of Horizon Therapeutics, succeeded in the first of two late-stage trials against the tough-to-treat autoimmune disorder.
Source: BioPharma Dive
The price since 22 Sep 2026: Acadia Healthcare (ACHC) versus the S&P 500
Since the first closing price after “Amgen reports a Phase 3 win with Sjögren’s drug candidate,” Acadia Healthcare (ACHC) is +5.96%. The S&P 500 fund (SPY) is -0.17% over the same days, a +6.14% difference versus the market.
Filings that name Acadia Healthcare (ACHC) around 22 Sep 2026
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 7 days after publication, inside 30 days. The filing is listed beside the story “Amgen reports a Phase 3 win with Sjögren’s drug candidate.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 11 days before publication, inside 30 days. The filing is listed beside the story “Amgen reports a Phase 3 win with Sjögren’s drug candidate.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 50 days before publication, inside 60 days. The filing is listed beside the story “Amgen reports a Phase 3 win with Sjögren’s drug candidate.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 54 days before publication, inside 60 days. The filing is listed beside the story “Amgen reports a Phase 3 win with Sjögren’s drug candidate.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 54 days before publication, inside 60 days. The filing is listed beside the story “Amgen reports a Phase 3 win with Sjögren’s drug candidate.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Acadia Healthcare (ACHC)
Companies tied to this story
- ACHC Acadia Healthcare
Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence in the 22 Sep 2026 story “Amgen reports a Phase 3 win with Sjögren’s drug candidate.” Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence in the 22 Sep 2026 story “Amgen reports a Phase 3 win with Sjögren’s drug candidate.” Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
In “Amgen reports a Phase 3 win with Sjögren’s drug candidate,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
In “Amgen reports a Phase 3 win with Sjögren’s drug candidate,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
For “Amgen reports a Phase 3 win with Sjögren’s drug candidate,” Davita (DVA) is linked, with no stored direction, medium confidence. Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
For “Amgen reports a Phase 3 win with Sjögren’s drug candidate,” GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
How “Amgen reports a Phase 3 win with Sjögren’s drug candidate” reaches Acadia Healthcare (ACHC)
Acadia Healthcare (ACHC) is the company in “Amgen reports a Phase 3 win with Sjögren’s drug candidate,” the 22 Sep 2026 this story story.
What ties Acadia Healthcare (ACHC) to the headline is this: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
A second company, Ascendis Pharma A/S (ASND), is listed for a different reason: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
The price range for Acadia Healthcare (ACHC), and the dates in the story
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. ATYR traded between 0.17 and 0.41 across 20 sessions. The latest close on file is 0.17.
How strong the case is around Acadia Healthcare (ACHC)
46 out of 100
“Amgen reports a Phase 3 win with Sjögren’s drug candidate” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.